Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Respiratory Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEM16A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM16A Extracellular Loop / Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 Expressed. |
View TMEM16A Products |
| Gene Delivery | TMEM16A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for preserving native 8-transmembrane conformation. |
View TMEM16A Products |
| Benchmark Ab | Anti-TMEM16A Recombinant Antibody Recombinant positive control for flow cytometry and functional blocking assays. |
View TMEM16A Products |
| Validator | TMEM16A siRNA Set For knockdown verification in functional assays. |
View TMEM16A Products |
| Related Target A | CFTR Synergistic chloride channel target in cystic fibrosis and respiratory disease drug screening. |
View CFTR Products |
| Related Target B | TMEM16B (ANO2) Closest homolog for selectivity and off-target safety counter-screening. |
View TMEM16B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentivirus-driven stable cell line generation for cell-based functional assays (electrophysiology/calcium flux). |
| Selectivity Against Homologs (TMEM16B/ANO2) | TMEM16B target verification reagents for counter-screening panels. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation |
| False Positives | Validated siRNA included for target specificity checks |
Live TMEM16A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEM16A therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule modulators (inhibitors for cancer/asthma, activators for cystic fibrosis). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective inhibitors that spare TMEM16B to prevent visual side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Enterprise Therapeutics, Novartis | Asthma, COPD, Cystic Fibrosis | Selectivity Assay (Need TMEM16B vs TMEM16A cell lines via Lentivirus) |
| Monoclonal Antibodies | Academic institutions, Biotech startups | GIST, HNSCC, Breast Cancer | Internalization & FACS Validation (Need Lentivirus for Stable Cell Lines) |
| Small Molecule Activators | Discovery-stage biotechs | Cystic Fibrosis, Dry Eye | Functional Calcium Flux (Need Lentivirus for high-expression cell lines) |